GENENTA SCIENCE(SP.ADR)/1 (F:K5F) — Market Cap & Net Worth
Market Cap & Net Worth: GENENTA SCIENCE(SP.ADR)/1 (K5F)
GENENTA SCIENCE(SP.ADR)/1 (F:K5F) has a market capitalization of $14.25 Million (€12.18 Million) as of September 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #26229 globally and #2251 in its home market, demonstrating a 10.17% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GENENTA SCIENCE(SP.ADR)/1's stock price €0.52 by its total outstanding shares 23432183 (23.43 Million). Also see total assets of GENENTA SCIENCE(SP.ADR)/1 for a full breakdown of the balance sheet.
GENENTA SCIENCE(SP.ADR)/1 Market Cap History: 2021 to 2026
GENENTA SCIENCE(SP.ADR)/1's market capitalization history from 2021 to 2026. Data shows change from $268.47 Million to $16.16 Million (-49.77% CAGR). Also see cash flow conversion of GENENTA SCIENCE(SP.ADR)/1 for how efficiently the company converts equity into cash flow.
GENENTA SCIENCE(SP.ADR)/1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GENENTA SCIENCE(SP.ADR)/1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check GENENTA SCIENCE(SP.ADR)/1 (K5F) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of K5F by Market Capitalization
Companies near GENENTA SCIENCE(SP.ADR)/1 in the global market cap rankings as of September 19, 2026. Review GENENTA SCIENCE(SP.ADR)/1 (K5F) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to GENENTA SCIENCE(SP.ADR)/1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
GENENTA SCIENCE(SP.ADR)/1 Historical Marketcap From 2021 to 2026
Between 2021 and today, GENENTA SCIENCE(SP.ADR)/1's market cap moved from $268.47 Million to $ 16.16 Million, with a yearly change of -49.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €16.16 Million | -52.42% |
| 2025 | €33.97 Million | -71.82% |
| 2024 | €120.54 Million | +2.33% |
| 2023 | €117.80 Million | -18.10% |
| 2022 | €143.82 Million | -46.43% |
| 2021 | €268.47 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of GENENTA SCIENCE(SP.ADR)/1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.25 Million USD |
| MoneyControl | $14.25 Million USD |
| MarketWatch | $14.25 Million USD |
| marketcap.company | $14.25 Million USD |
| Reuters | $14.25 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GENENTA SCIENCE(SP.ADR)/1
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for us… Read more